Dexamethasone (IV)

DRUG10 trials

Sponsors

Bristol-Myers Squibb, Cancer Trials Ireland, Al-Quds University, Valerie Zaphiratos, Ziekenhuis Oost-Limburg

Conditions

AnaesthesiaCD - Crohn's DiseaseCesarean DeliveryCesarean Section PainDeep Neck InfectionsDexamethasoneHealth-Related Quality-of-LifeInflammatory Bowel Disease (IBD)

Phase 2

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruitingNCT05123131

Cancer Trials IrelandMultiple Myeloma

Start: 2022-04-01End: 2027-12-15Updated: 2025-07-08

Phase 3

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

CompletedNCT01239797

Bristol-Myers SquibbLymphoma, Multiple Myeloma

Start: 2011-06-20End: 2021-04-21Updated: 2022-06-01

Phase 4

The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study

RecruitingNCT07378215

Ziekenhuis Oost-LimburgHealth-Related Quality-of-Life, Postoperative Quality of Recovery, Quality of Life

Start: 2026-01-30End: 2027-02-01Target: 224Updated: 2026-04-08

Intravenous Dexamethasone With Single-Shot Versus Continuous Brachial Plexus Block for Rebound Pain After Shoulder Surgery

Not yet recruitingNCT07699744

Seoul National University HospitalPain, Postoperative, Rebound Pain, Rotator Cuff Injuries +1

Start: 2026-07-15End: 2027-07-15Target: 92Updated: 2026-07-13

Effect of Single-Dose Dexamethasone on Postoperative Pain After Cesarean Section Under Spinal Anesthesia

CompletedNCT07718360

KRL Hospital, IslamabadCesarean Section Pain, Postoperative Pain, Spinal Anesthesia

Start: 2024-03-01End: 2024-09-01Updated: 2026-07-21

Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION)

Not yet recruitingNCT07777276

Telethon Kids InstituteAnaesthesia, Paediatric Surgery, Postoperative Behaviour +3

Start: 2026-08-17End: 2029-08-17Target: 500Updated: 2026-08-20

Unknown Phase

Effect of IV Dexamethasone on Post-op Urinary Retention After Spinal Anesthesia

Active, not recruitingNCT07077850

Al-Quds UniversityPost Operative Urinary Retention, Spinal Aneshtesia

Start: 2025-08-20End: 2026-12-20Updated: 2026-07-14

Dexamethasone for Post-operative Pain After Cesarean Delivery Under Neuraxial Anesthesia.

CompletedNCT07257406

Valerie ZaphiratosCesarean Delivery, Dexamethasone, Pregnancy

Start: 2018-09-13End: 2026-01-20Updated: 2026-08-05

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

RecruitingNCT07385131

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCD - Crohn's Disease, Inflammatory Bowel Disease (IBD), UC - Ulcerative Colitis

Start: 2025-10-08End: 2029-12-31Target: 300Updated: 2026-02-03

Steroids in the Treatment of Deep Neck Space Infections

CompletedNCT07815028

Dr. Lutfi Kirdar Kartal Training and Research HospitalDeep Neck Infections

Start: 2025-03-26End: 2026-06-05Updated: 2026-09-11

Related Papers

Using electronic health records to derive a synthetic control arm for a historical trial on relapsed/refractory multiple myeloma.

Journal of Clinical Oncology2022-06-01

Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.

2021-11-263 citations

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

2020-09-0496 citations

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

Blood2019-11-131 citations

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Future Oncology2019-02-2829 citations

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

Cancer2018-09-11139 citations

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study

Annals of Hematology2018-09-0318 citations

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2018-05-2011 citations

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

2018-02-1513 citations

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Blood2017-12-074 citations

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth

British Journal of Haematology2017-07-05131 citations

Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2017-05-209 citations

An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.

2017-01-098 citations

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Blood2016-12-02

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.

2016-09-2714 citations

ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)—Identifying responders by subset analysis.

Journal of Clinical Oncology2016-05-208 citations

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

Blood2015-12-0328 citations

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

New England Journal of Medicine2015-06-021301 citations

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2015-05-2022 citations